Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis

References

• Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology45(1), 242–249 (2007).
   PubMed Web of Science ®Google Scholar
• Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest.117(3), 539–548 (2007).
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest.115(2), 209–218 (2005).
   PubMed Web of Science ®Google Scholar
• Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig. Liver Dis.36(4), 231–242 (2004).
   PubMedGoogle Scholar
• Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin. Chim. Acta364(1–2), 33–60 (2006).
   PubMed Web of Science ®Google Scholar
• Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front. Biosci.7, D1720–D1726 (2002).
   PubMedGoogle Scholar
• Bissell DM, Roulot D, George J. Transforming growth factor β and the liver. Hepatology34(5), 859–867 (2001).
   PubMed Web of Science ®Google Scholar
• Duffield JS, Forbes SJ, Constandinon CM et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest.115(1), 56–65 (2005).
   PubMed Web of Science ®Google Scholar
• Imamura M, Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology128(1), 138–146 (2005).
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor β: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology11(4), 599–605 (1990).
   PubMed Web of Science ®Google Scholar
• Novobrantseva TI, Majeau GR, Amatucci A et al. Attenuated liver fibrosis in the absence of B cells. J. Clin. Invest.115(11), 3072–3082 (2005).
   PubMed Web of Science ®Google Scholar
• Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl Acad. Sci. USA94(20), 10663–10668 (1997).
   PubMed Web of Science ®Google Scholar
• Saito JM, Bostick MK, Campe CB, Xu J, Maher JJ. Infiltrating neutrophils in bile duct-ligated livers do not promote hepatic fibrosis. Hepatol. Res.25(2), 180–191 (2003).
   PubMedGoogle Scholar
• Jeong WI, Lee CS, Park SJ, Chung JY, Jeong KS. Kinetics of macrophages, myofibroblasts and mast cells in carbon tetrachloride-induced rat liver cirrhosis. Anticancer Res.22(2A), 869–877 (2002).
   PubMedGoogle Scholar
• Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology130(2), 435–452 (2006).
   PubMed Web of Science ®Google Scholar
• Melhem A, Muhanna N, Bishara A et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol.45(1), 60–71 (2006).
   PubMed Web of Science ®Google Scholar
• Mehal W Z. Activation-induced cell death of hepatic stellate cells by the innate immune system. Gastroenterology130(2), 600–603 (2006).
   PubMedGoogle Scholar
• Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors. Transpl. Immunol.10(2–3), 147–164 (2002).
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu. Rev. Immunol.23, 225–274 (2005).
   PubMed Web of Science ®Google Scholar
• Ortaldo JR, Young HA. Mouse Ly49 NK receptors: balancing activation and inhibition. Mol. Immunol.42(4), 445–450 (2005).
   PubMedGoogle Scholar
• Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science306(5701), 1517–1519 (2004).
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Bakker AB, McClanahan T et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity12(6), 721–727 (2000).
   PubMed Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science285(5428), 727–729 (1999).
   PubMed Web of Science ®Google Scholar
• Cosman D, Müllberg J, Sutherland CL et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity14(2), 123–133 (2001).
   PubMed Web of Science ®Google Scholar
• Chalupny NJ, Sutherland CL, Lawrence WA et al. ULBP4 is a novel ligand for human NKG2D. Biochem. Biophys. Res. Commun.305(1), 129–135 (2003).
   PubMedGoogle Scholar
• Kenna T, Golden-Mason L, Porcelli SA et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol.171(4), 1775–1779 (2003).
   PubMed Web of Science ®Google Scholar
• Obara H, Nagasaki K, Hsieh CL et al. IFN-γ, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. Am J. Transplant.5(9), 2094–2103 (2005).
   PubMedGoogle Scholar
• Sun R, Tian Z, Kulkarni S, Gao B. IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J. Immunol.172(9), 5648–5655 (2004).
   PubMed Web of Science ®Google Scholar
• Vermijlen D, Luo D, Froelich CJ et al. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J. Leukoc. Biol.72(4), 668–676 (2002).
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Smyth MJ et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med.7(1), 94–100 (2001).
   PubMed Web of Science ®Google Scholar
• Barajas M, Mazzolini G, Genové G et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology33(1), 52–61 (2001).
   PubMed Web of Science ®Google Scholar
• Ortaldo JR, Winkler-Pickett RT, Bere EW, Watanabe M, Murphy WJ, Wiltrout RH. In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J. Immunol.175(2), 693–699 (2005).
   PubMed Web of Science ®Google Scholar
• Péron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3-ligand administration inhibits liver metastases: role of NK cells. J. Immunol.161(11), 6164–6170 (1998).
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Iwatsuki S, Herberman RB, Whiteside TL. Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors. Int. J. Cancer46(5), 878–883 (1990).
   PubMedGoogle Scholar
• Hata K, Van Thiel DH, Herberman RB, Whiteside TL. Natural killer activity of human liver-derived lymphocytes in various liver diseases. Hepatology14(3), 495–503 (1991).
   PubMedGoogle Scholar
• Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer83(1), 58–63 (1998).
   PubMed Web of Science ®Google Scholar
• Chuang WL, Liu HW, Chang WY. Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer65(4), 926–930 (1990).
   PubMedGoogle Scholar
• Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr. Opin. Immunol.17(1), 29–35 (2005).
   PubMed Web of Science ®Google Scholar
• Chen Y, Wei H, Gao B, Hu Z, Zheng S, Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J. Viral. Hepat.12(1), 38–45 (2005).
   PubMedGoogle Scholar
• Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ. Natural killer cells inhibit hepatitis C virus expression. J. Leukoc. Biol.76(6), 1171–1179 (2004).
   PubMedGoogle Scholar
• Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science305(5685), 872–874 (2004).
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver. Transpl.12(3), 363–372 (2006).
   PubMedGoogle Scholar
• Ahmad A, Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J. Leukoc. Biol.76(4), 743–759 (2004).
   PubMed Web of Science ®Google Scholar
• Dong Z, Wei H, Sun R, Hu Z, Gao B, Tian Z. Involvement of natural killer cells in PolyI:C-induced liver injury. J. Hepatol.41(6), 966–973 (2004).
   PubMed Web of Science ®Google Scholar
• Ochi M, Ohdan H, Mitsuta H et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology39(5), 1321–1331 (2004).
   PubMedGoogle Scholar
• Sun R, Gao B. Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-γ). Gastroenterology127(5), 1525–1539 (2004).
   PubMed Web of Science ®Google Scholar
• Sun R, Park O, Horiguchi N et al. STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. Hepatology44(4), 955–966 (2006).
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Muto Y, Maeda T et al. Natural killer cell may impair liver regeneration in fulminant hepatic failure. Gastroenterol. Jpn28(Suppl. 4), 40–44 (1993).
   PubMedGoogle Scholar
• Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology44(6), 1441–1451 (2006).
   PubMed Web of Science ®Google Scholar
• Rockey DC, Chung JJ. Interferon γ inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J. Invest. Med.42(4), 660–670 (1994).
   PubMedGoogle Scholar
• Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon α and γ inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology21(4), 1003–1010 (1995).
   PubMed Web of Science ®Google Scholar
• Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature397(6721), 710–713 (1999).
   PubMed Web of Science ®Google Scholar
• Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology37(1), 87–95 (2003).
   PubMed Web of Science ®Google Scholar
• Mühlen KA, Schümann J, Wittke F et al. NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice. J. Immunol.172(5), 3034–3041 (2004).
   PubMedGoogle Scholar
• Liu ZX, Govindarajan S, Okamoto S, Dennert G. NK cells cause liver injury and facilitate the induction of T cell-mediated Immunity to a viral liver infection. J. Immunol.164(12), 6480–6486 (2000).
   PubMed Web of Science ®Google Scholar
• Jiang D, Liang J, Hodge J et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J. Clin. Invest.114(2), 291–299 (2004).
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim HY, Kim S, Chung JH, Park WS, Chung DH. Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-γ. Am. J. Pathol.167(5), 1231–1241 (2005).
   PubMed Web of Science ®Google Scholar
• Kimura T, Ishii Y, Morishima Y et al. Treatment with α-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis. J. Immunol.172(9), 5782–5789 (2004).
   PubMed Web of Science ®Google Scholar
• Pár G, Rukavina D, Podack ER et al. Decrease in CD3-negative-CD8dim(+) and Vδ2/Vγ9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. J. Hepatol.37(4), 514–522 (2002).
   PubMedGoogle Scholar
• Kawarabayashi N, Seki S, Hatsuse K et al. Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology32(5), 962–969 (2000).
   PubMedGoogle Scholar
• Morishima C, Paschal DM, Wang CC et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology43(3), 573–580 (2006).
   PubMedGoogle Scholar
• Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med.132(7), 517–524 (2000).
   PubMed Web of Science ®Google Scholar
• Guerret S, Desmoulière A, Chossegros P et al. Long-term administration of interferon-α in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J. Viral. Hepat.6(2), 125–133 (1999).
   PubMedGoogle Scholar
• Inagaki Y, Nemoto T, Kushida M et al. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology38(4), 890–899 (2003).
   PubMed Web of Science ®Google Scholar
• Rockey DC, Maher JJ, Jarnagin WR, Gabbiani G, Friedman SL. Inhibition of rat hepatic lipocyte activation in culture by interferon-γ. Hepatology16(3), 776–784 (1992).
   PubMed Web of Science ®Google Scholar
• Weng HL, Wang BE, Jia JD et al. Effect of interferon-γ on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin. Gastroenterol. Hepatol.3(8), 819–828 (2005).
   PubMedGoogle Scholar
• Muir AJ, Sylvestre PB, Rockey DC. Interferon γ-1b for the treatment of fibrosis in chronic hepatitis C infection. J. Viral. Hepat.13(5), 322–328 (2006).
   PubMedGoogle Scholar
• Pockros PJ, Jeffers L, Afdhal N et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology45(3), 569–578 (2007).
   PubMed Web of Science ®Google Scholar
• Muddu AK, Guha IN, Elsharkawy AM, Mann DA. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int. J. Biochem. Cell. Biol.39(4), 695–714 (2007).
   PubMed Web of Science ®Google Scholar
• Yokoyama WM. Natural killer cell receptors specific for major histocompatibility complex class I molecules. Proc. Natl Acad. Sci. USA92(8), 3081–3085 (1995).
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Vitale M. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol.14, 619–648 (1996).
   PubMed Web of Science ®Google Scholar
• Braud VM, Allan DS, O’Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature391(6669), 795–799 (1998).
   PubMed Web of Science ®Google Scholar
• Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med.188(10), 1841–1848 (1998).
   PubMed Web of Science ®Google Scholar
• Biassoni R, Cantoni C, Pende D et al. Human natural killer cell receptors and co-receptors. Immunol. Rev.181, 203–214 (2001).
   PubMed Web of Science ®Google Scholar
• Arnon TI, Achdout H, Levi O et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol.6(5), 515–523 (2005).
   PubMed Web of Science ®Google Scholar
• Mandelboim O, Lieberman N, Lev M et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature409(6823), 1055–1060 (2001).
   PubMed Web of Science ®Google Scholar
• Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol.31(9), 2680–2689 (2001).
   PubMed Web of Science ®Google Scholar
• Arnon TI, Achdout H, Lieberman N et al. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood103(2), 664–672 (2004).
   PubMed Web of Science ®Google Scholar
• Zilka A, Landau G, Hershkovitz O et al. Characterization of the heparin/heparan sulfate binding site of the natural cytotoxicity receptor NKp46. Biochemistry44(44), 14477–11485 (2005).
   PubMedGoogle Scholar
• Lee N, Llano M, Carretero M et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA95(9), 5199–51204 (1998).
   PubMed Web of Science ®Google Scholar
• Vance RE, Jamieson AM, Raulet DH. Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J. Exp. Med.190(12), 1801–1812 (1999).
   PubMed Web of Science ®Google Scholar